NVIDIA Corporation secures silicon photonics pipeline through expanded partnership with Coherent Corp.
NVIDIA Corporation and Coherent Corp. strike a multibillion-dollar optics deal to scale AI data centers. Discover what it means for investors and competitors.
From Utah breccias to Trail smelters: will Blue Moon Metals Inc. control the chokepoints?
Blue Moon Metals Inc. acquires Apex from Teck Resources Limited to build a US critical minerals hub. Explore the strategy reshaping North American supply chains.
Is Edison Lithium Corp. quietly pivoting from lithium to Quebec gold?
Edison Lithium Corp. options Quebec gold and copper assets in Casa Berardi. Discover what this staged earn-in means for strategy and investors.
Will HBT Financial’s $1.8bn asset addition shift competitive dynamics in Illinois banking?
HBT Financial completes CNB Bank Shares merger, adding $1.8B in assets. Discover what this means for Midwest banking and investors.
Can drone data become the next high-margin growth driver for Cellebrite Ltd.? (NASDAQ: CLBT)
Cellebrite Ltd. expands into drone forensics with SCG Canada, Inc. acquisition. Discover how UAV data could reshape AI-powered investigations.
Does FDA clearance across three HLA subtypes de-risk TScan Therapeutics’ platform strategy?
FDA clears TSC-102-A01 and TSC-102-A03 for TScan Therapeutics. Explore how expanded HLA reach reshapes its heme cell therapy strategy.
How FIREFLY1 data positioned Ojemda for conditional EU approval in pediatric glioma
How FIREFLY1 data positioned Ipsen’s Ojemda for conditional EU approval in pediatric glioma and what it means for investors and competitors.
Will mavorixafor’s EU path mirror its U.S. regulatory breakthrough in WHIM syndrome?
X4 Pharmaceuticals (NASDAQ: XFOR) wins EMA backing for mavorixafor. Explore what EU approval could mean for revenue, risk, and rare disease strategy.
How FDA-aligned endpoints position inFoods IBS alongside drug therapies
Biomerica, Inc. aligns inFoods IBS with FDA drug endpoints and secures Medicare pricing. See what this means for IBS competitors and investors.
SCY-247 intravenous trial signals strategic shift in SCYNEXIS, Inc.’s antifungal pipeline
SCYNEXIS, Inc. advances IV SCY-247 into Phase 1. Discover what this signals for antifungal resistance and hospital markets.